Vyvanse (lisdexamfetamine)

Lisdexamfetamine is used for ADHD in adults and children aged six and older, and moderate-to-severe binge eating disorder in adults. It is not approved as a weight-loss treatment.

The treatment indication matters when evaluating a prescription. Approval for binge eating disorder does not mean that an amphetamine medicine is appropriate for general appetite control or obesity.

• ADHD: treatment is part of an individual clinical care plan.
• Binge eating disorder: the approved indication is for adults.
• Suitability depends on the patient’s medical and psychiatric history.

Sources: FDA — Approval of generic lisdexamfetamine capsules and chewable tablets

Lisdexamfetamine is a prodrug: the body converts it into dextroamphetamine and L-lysine. Its stimulant effects involve dopamine and norepinephrine signaling.

Sources: FDA — Vyvanse prescribing information, revised April 2026

Sleep problems, reduced appetite, dry mouth and nausea can occur. Report persistent or concerning symptoms to the prescriber.

Commonly reported problems

• Decreased appetite or weight loss
• Insomnia
• Dry mouth
• Nausea or abdominal discomfort
• Anxiety or restlessness

Serious effects requiring assessment

• Chest pain, fainting or significant heart symptoms
• New hallucinations or marked mood changes
• Possible serotonin syndrome
• Circulation changes in fingers or toes
• Slowed growth or weight gain in children

This list is not a complete adverse-effect profile. The prescribing information describes monitoring and precautions for each risk.

Sources: MedlinePlus — Lisdexamfetamine

The prescription depends on the indication, formulation, response and kidney function. Follow the specific product instructions; do not change the dose or schedule independently.

Capsules and chewable tablets require their own administration instructions. Ask the pharmacist before opening a capsule, changing dosage forms or substituting a product. This summary does not replace the Medication Guide.

Sources: MedlinePlus — Lisdexamfetamine

Taking a stimulant without a prescription or in a way other than prescribed can cause serious harm. Physical dependence and addiction describe different clinical issues.

• Do not share or sell the medicine.
• Store it securely to reduce accidental or unauthorized access.
• Discuss treatment changes with the prescriber rather than abruptly changing regular use.

Sources: FDA — Vyvanse prescribing information, revised April 2026

MAO inhibitors are an important contraindication. Other serotonergic medicines and certain drugs affecting dextroamphetamine exposure also require review.

• Provide a complete medication and supplement list.
• Tell the clinician about cardiovascular and psychiatric history.
• Ask before combining prescription stimulants or changing other medicines.

An interaction review must use the actual products and doses involved. A short category list cannot establish that an individual combination is safe.

Sources: FDA — Vyvanse prescribing information, revised April 2026

A suspected overdose requires urgent medical advice. Seizures, collapse, trouble breathing or inability to wake require emergency services.

Do not wait for an online response or try to manage a severe reaction by changing another medicine. Keep the product information available for the medical team when possible.

Sources: MedlinePlus — Lisdexamfetamine

Lisdexamfetamine is federally listed in Schedule II. A controlled-drug classification is distinct from permission for a specific online prescription or dispensing transaction.

Sources: DEA — Controlled substances alphabetical list (October 2026)